Sickle cell screening in US3 and the post-US3 period
| Region of Uganda . | US3 (1 year) (97 631 samples) . | Post-US3 (3 years) (112 352 samples) . | ||
|---|---|---|---|---|
| SCT (%) . | SCD (%) . | SCT (%) . | SCD (%) . | |
| Central 1 | 1896 (12.9) | 69 (0.5) | 2497 (13.1) | 144 (0.8) |
| Central 2 | 1566 (14.1) | 94 (0.8) | 1646 (14.4) | 128 (1.1) |
| East Central | 1306 (19.9) | 96 (1.5) | 2128 (19.2) | 225 (2.0) |
| Kampala | 1835 (13.6) | 90 (0.7) | 3533 (13.7) | 235 (0.9) |
| Mid-Eastern | 752 (15.5) | 60 (1.2) | 1004 (17.4) | 115 (2.0) |
| Mid-Northern | 2445 (19.2) | 160 (1.3) | 4067 (18.5) | 394 (1.8) |
| Mid-Western | 1431 (11.1) | 64 (0.5) | 848 (14.5) | 59 (1.0) |
| North-Eastern | 702 (15.8) | 46 (1.0) | 1100 (16.4) | 100 (1.5) |
| South-Western | 631 (4.6) | 23 (0.2) | 135 (6.4) | 3 (0.1) |
| West Nile | 415 (13.8) | 14 (0.5) | 422 (16.5) | 19 (0.7) |
| Total | 12 979 (13.3) | 716 (0.7) | 17 380 (15.5) | 1422 (1.3) |
| Region of Uganda . | US3 (1 year) (97 631 samples) . | Post-US3 (3 years) (112 352 samples) . | ||
|---|---|---|---|---|
| SCT (%) . | SCD (%) . | SCT (%) . | SCD (%) . | |
| Central 1 | 1896 (12.9) | 69 (0.5) | 2497 (13.1) | 144 (0.8) |
| Central 2 | 1566 (14.1) | 94 (0.8) | 1646 (14.4) | 128 (1.1) |
| East Central | 1306 (19.9) | 96 (1.5) | 2128 (19.2) | 225 (2.0) |
| Kampala | 1835 (13.6) | 90 (0.7) | 3533 (13.7) | 235 (0.9) |
| Mid-Eastern | 752 (15.5) | 60 (1.2) | 1004 (17.4) | 115 (2.0) |
| Mid-Northern | 2445 (19.2) | 160 (1.3) | 4067 (18.5) | 394 (1.8) |
| Mid-Western | 1431 (11.1) | 64 (0.5) | 848 (14.5) | 59 (1.0) |
| North-Eastern | 702 (15.8) | 46 (1.0) | 1100 (16.4) | 100 (1.5) |
| South-Western | 631 (4.6) | 23 (0.2) | 135 (6.4) | 3 (0.1) |
| West Nile | 415 (13.8) | 14 (0.5) | 422 (16.5) | 19 (0.7) |
| Total | 12 979 (13.3) | 716 (0.7) | 17 380 (15.5) | 1422 (1.3) |
Samples were collected using targeted screening from the districts with the highest burden. Results confirm the high burden of SCT and SCD in Uganda, especially in the East Central and Mid-Northern regions.